Immune response against Trypanosoma cruzi antigens in Cebus apella monkeys
- PMID: 8367672
Immune response against Trypanosoma cruzi antigens in Cebus apella monkeys
Abstract
The american primate Cebus apella has been used as an experimental model for the study of acute and chronic Chagas' disease. The antibody response elicited by 4 x 10(6) blood trypnomastigotes injected into four monkeys was analysed. Peak titres of IgM and IgG of anti-Trypanosoma cruzi antibodies were found at day 22, and between days 20 and 40 post-infection (p.i.), respectively. The ability of a Mr 37kDa (T37K) glycoprotein purified from T. cruzi epimastigotes to generate IgG anti-T. cruzi antibodies in monkeys, and protect them against a challenge with trypomastigotes, was also studied. Monkeys non-immunized with T37K reached peak values of parasitaemia between days 18 and 21 post-infection, whereas immunized monkeys had lower parasitaemias without important variation. Anti-T37K antibodies in immunized monkeys decreased from day 2 with the lowest titres between days 14 to 22 p.i., coincident with the peak of parasitaemia in control non-immunized monkeys. These results suggest that anti-T37K antibodies could be responsible for the low parasitaemia detected in immunized monkeys.
Similar articles
-
Acute Chagas' disease in non-human primates. 1. Chronology of clinical events, clinical chemistry, ECG, radiology, parasitemia, and immunological parameters in the Cebus apella monkey.Trop Med Parasitol. 1988 Mar;39(1):51-5. Trop Med Parasitol. 1988. PMID: 3133743
-
Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.Vaccine. 2015 Mar 3;33(10):1274-83. doi: 10.1016/j.vaccine.2015.01.044. Epub 2015 Jan 25. Vaccine. 2015. PMID: 25625671
-
Evaluation of immune responses raised against Tc13 antigens of Trypanosoma cruzi in the outcome of murine experimental infection.Parasitology. 2008 Mar;135(3):347-57. doi: 10.1017/S0031182007003873. Epub 2007 Nov 9. Parasitology. 2008. PMID: 17991305
-
The targets of the lytic antibody response against Trypanosoma cruzi.Parasitol Today. 2000 Jan;16(1):31-4. doi: 10.1016/s0169-4758(99)01581-1. Parasitol Today. 2000. PMID: 10637586 Review.
-
Vaccine development against Trypanosoma cruzi and Chagas disease.Adv Parasitol. 2011;75:121-46. doi: 10.1016/B978-0-12-385863-4.00006-X. Adv Parasitol. 2011. PMID: 21820554 Review.
Cited by
-
Cross-reactivity studies and differential serodiagnosis of human infections caused by Trypanosoma cruzi and Leishmania spp; use of immunoblotting and ELISA with a purified antigen (Ag163B6).Clin Exp Immunol. 1994 Sep;97(3):417-23. doi: 10.1111/j.1365-2249.1994.tb06104.x. Clin Exp Immunol. 1994. PMID: 8082296 Free PMC article.
-
Translational challenges of animal models in Chagas disease drug development: a review.Drug Des Devel Ther. 2015 Aug 19;9:4807-23. doi: 10.2147/DDDT.S90208. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26316715 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical